Patents by Inventor Paul Howley

Paul Howley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA)
    Publication number: 20110250693
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
    Type: Application
    Filed: April 15, 2011
    Publication date: October 13, 2011
    Inventors: Paul HOWLEY, Sonja Leyrer
  • Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
    Patent number: 8034354
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: October 11, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA)
    Publication number: 20110244574
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
    Type: Application
    Filed: April 15, 2011
    Publication date: October 6, 2011
    Inventors: Paul Howley, Sonja Leyrer
  • Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
    Patent number: 8029800
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 4, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
    Patent number: 8021669
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: September 20, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD
    Publication number: 20110217757
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Application
    Filed: May 12, 2011
    Publication date: September 8, 2011
    Applicant: BAVARIAN NORDIC A/S
    Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER-HENSCHEL, INGMAR RATHE, EVA FELDER, KARL HELLER
  • MODIFIED VACCINIA ANKARA VIRUS VARIANT
    Publication number: 20110182933
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
    Type: Application
    Filed: March 22, 2011
    Publication date: July 28, 2011
    Applicant: BAVARIAN NORDIC A/S
    Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER
  • MODIFIED VACCINIA ANKARA VIRUS VARIANT
    Publication number: 20110182932
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
    Type: Application
    Filed: March 22, 2011
    Publication date: July 28, 2011
    Applicant: BAVARIAN NORDIC A/S
    Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER
  • Modified vaccinia ankara virus variant and cultivation method
    Patent number: 7964396
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
  • Modified vaccinia ankara virus variant and cultivation method
    Patent number: 7964395
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
  • Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
    Patent number: 7964374
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • Modified vaccinia ankara virus variant and cultivation method
    Patent number: 7964398
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
  • Modified Vaccinia Ankara virus variant
    Patent number: 7939086
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 10, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
  • Modified Vaccinia Ankara virus variant
    Patent number: 7923017
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: April 12, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
  • RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME
    Publication number: 20110053260
    Abstract: The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.
    Type: Application
    Filed: September 30, 2010
    Publication date: March 3, 2011
    Inventors: PAUL HOWLEY, Sonja Leyrer
  • RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRUS GENOME
    Publication number: 20110053259
    Abstract: The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.
    Type: Application
    Filed: September 30, 2010
    Publication date: March 3, 2011
    Inventors: PAUL HOWLEY, SONJA LEYRER
  • INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA)
    Publication number: 20100303856
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
    Type: Application
    Filed: May 19, 2009
    Publication date: December 2, 2010
    Inventors: Paul Howley, Sonja Leyrer
  • MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD
    Publication number: 20100279386
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Application
    Filed: July 14, 2010
    Publication date: November 4, 2010
    Applicant: BAVARIAN NORDIC A/S
    Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER-HENSCHEL, INGMAR RATHE, EVA FELDER, KARL HELLER
  • INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA
    Publication number: 20100196992
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Application
    Filed: February 26, 2009
    Publication date: August 5, 2010
    Inventors: PAUL HOWLEY, SONJA LEYRER, PAUL CHAPLIN, EVA FELDER
  • INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA
    Publication number: 20100183663
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Application
    Filed: February 26, 2009
    Publication date: July 22, 2010
    Inventors: PAUL HOWLEY, SONJA LEYRER, PAUL CHAPLIN, EVA FELDER